Gain Therapeutics(GANX)
$0.94-0.10 (-9.62%)
GANX
Gain Therapeutics stock drug pipeline
$0.94
At close:-0.10 (-9.62%)
Want to see GANX full AI Analyst Report?
Gain Therapeutics (GANX) Drug Pipeline
469 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Gt-02287 | Parkinson Disease | Phase I | Recruiting | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease | Dec 09, 2024 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Gt-02287 | Phase I | Parkinson Disease | Recruiting | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease | Dec 09, 2024 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Gain Therapeutics, Inc. (GANX) have in its pipeline
Gain Therapeutics GANX is currently developing the following drugs: Gt-02287. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

